ARTICLE | Emerging Company Profile
Calydon: Lysing prostate cancer
November 23, 1998 8:00 AM UTC
Calydon wants to cure prostate cancer and is pursuing an approach that moves past traditional gene therapies, which encode for a therapeutic gene, to using regulatory genes to create cytolytic (cell lysing) viruses.
The company's core technology, Attenuated Replication-Competent Adenovirus (ARCA), was developed to incorporate the discovery of PSE (prostate tissue-specific enhancer), a gene that regulates the growth of prostate tissue...